RT Journal Article
T1 Therapeutic targeting of<scp>TGF</scp>‐β in lung cancer
A1 Aftabi, Sajjad
A1 Barzegar Behrooz, Amir
A1 Cordani, Marco
A1 Rahiman, Niloufar
A1 Sadeghdoust, Mohammadamin
A1 Aligolighasemabadi, Farnaz
A1 Pistorius, Stephen
A1 Alavizadeh, Seyedeh Hoda
A1 Taefehshokr, Nima
A1 Ghavami, Saeid
AB Transforming growth factor-β (TGF-β) plays a complex role in lung cancer pathophysiology, initially acting as a tumor suppressor by inhibiting early-stage tumor growth. However, its role evolves in the advanced stages of the disease, where it contributes to tumor progression not by directly promoting cell proliferation but by enhancing epithelial–mesenchymal transition (EMT) and creating a conducive tumor microenvironment. While EMT is typically associated with enhanced migratory and invasive capabilities rather than proliferation per se, TGF-β's influence on this process facilitates the complex dynamics of tumor metastasis. Additionally, TGF-β impacts the tumor microenvironment by interacting with immune cells, a process influenced by genetic and epigenetic changes within tumor cells. This interaction highlights its role in immune evasion and chemoresistance, further complicating lung cancer therapy. This review provides a critical overview of recent findings on TGF-β's involvement in lung cancer, its contribution to chemoresistance, and its modulation of the immune response. Despite the considerable challenges encountered in clinical trials and the development of new treatments targeting the TGF-β pathway, this review highlights the necessity for continued, in-depth investigation into the roles of TGF-β. A deeper comprehension of these roles may lead to novel, targeted therapies for lung cancer. Despite the intricate behavior of TGF-β signaling in tumors and previous challenges, further research could yield innovative treatment strategies.
PB Wiley
SN 1742-464X
YR 2024
FD 2024
LK https://hdl.handle.net/20.500.14352/118218
UL https://hdl.handle.net/20.500.14352/118218
LA spa
NO Aftabi, S., Barzegar Behrooz, A., Cordani, M., Rahiman, N., Sadeghdoust, M., Aligolighasemabadi, F., Pistorius, S., Alavizadeh, S.H., Taefehshokr, N. and Ghavami, S. (2025), Therapeutic targeting of TGF-β in lung cancer. FEBS J. https://doi.org/10.1111/febs.17234
NO MC was supported by grant RYC2021-031003I funded by MICIU/AEI/10.13039/501100011033 and by European Union NextGenerationEU/PRTR.
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO European Commission
DS Docta Complutense
RD 17 may 2025